MRI and PET of bone marrow in lymphoproliferative diseases

In lymphoproliferative diseases, bone marrow involvement (BMI) is an essential parameter influencing staging, prognosis and treatment. In addition to pathological analysis of blind bone marrow biopsy, MRI and PET can help to (a) estimate initial BMI and assess the stage of disease, (b) indicate prog...

Full description

Bibliographic Details
Main Authors:	Rahmouni, A., Meignan, M., Divine, M., Luciani, A., Haioun, C., Montazel, J.-L., Kobeiter, H.
Format:	Online
Language:	English
Published:	BioMed Central 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448641/

id	pubmed-4448641
recordtype	oai_dc
spelling	pubmed-44486412015-05-30 MRI and PET of bone marrow in lymphoproliferative diseases Rahmouni, A. Meignan, M. Divine, M. Luciani, A. Haioun, C. Montazel, J.-L. Kobeiter, H. Review In lymphoproliferative diseases, bone marrow involvement (BMI) is an essential parameter influencing staging, prognosis and treatment. In addition to pathological analysis of blind bone marrow biopsy, MRI and PET can help to (a) estimate initial BMI and assess the stage of disease, (b) indicate prognosis and (c) assess response to treatment. Regarding diagnosis, the MR patterns of focal and diffuse BMI will be reviewed, and compared to the MR appearance of normal marrow. The technique and the results of dynamic contrast-enhanced (DCE) MRI regarding normal and tumoral marrow will be detailed. An approach of the perfusion parameters of normal and tumoral marrow will thus be presented. The changes of MR patterns linked to BMI will be described after treatment and correlated to the response to treatment of patients with lymphoma and myeloma. Although 18F-FDG-PET has been extensively studied in the management of lymphoma, few studies have examined its value for assessing BMI. 18F-FDG-PET seems to be accurate for this purpose in patients with lymphoma and myeloma. The limitations of MR imaging and 18F-FDG-PET will be detailed. In conclusion, MRI and PET imaging including the functional approach of perfusion by DCE-MR imaging and glucose uptake by 18F-FDG-PET can contribute to the management of patients with lymphoproliferative diseases by its ability to analyse BMI. BioMed Central 2015-05-05 2003 /pmc/articles/PMC4448641/ http://dx.doi.org/10.1102/1470-7330.2003.0017 Text en © International Cancer Imaging Society 2003
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Rahmouni, A. Meignan, M. Divine, M. Luciani, A. Haioun, C. Montazel, J.-L. Kobeiter, H.
spellingShingle	Rahmouni, A. Meignan, M. Divine, M. Luciani, A. Haioun, C. Montazel, J.-L. Kobeiter, H. MRI and PET of bone marrow in lymphoproliferative diseases
author_facet	Rahmouni, A. Meignan, M. Divine, M. Luciani, A. Haioun, C. Montazel, J.-L. Kobeiter, H.
author_sort	Rahmouni, A.
title	MRI and PET of bone marrow in lymphoproliferative diseases
title_short	MRI and PET of bone marrow in lymphoproliferative diseases
title_full	MRI and PET of bone marrow in lymphoproliferative diseases
title_fullStr	MRI and PET of bone marrow in lymphoproliferative diseases
title_full_unstemmed	MRI and PET of bone marrow in lymphoproliferative diseases
title_sort	mri and pet of bone marrow in lymphoproliferative diseases
description	In lymphoproliferative diseases, bone marrow involvement (BMI) is an essential parameter influencing staging, prognosis and treatment. In addition to pathological analysis of blind bone marrow biopsy, MRI and PET can help to (a) estimate initial BMI and assess the stage of disease, (b) indicate prognosis and (c) assess response to treatment. Regarding diagnosis, the MR patterns of focal and diffuse BMI will be reviewed, and compared to the MR appearance of normal marrow. The technique and the results of dynamic contrast-enhanced (DCE) MRI regarding normal and tumoral marrow will be detailed. An approach of the perfusion parameters of normal and tumoral marrow will thus be presented. The changes of MR patterns linked to BMI will be described after treatment and correlated to the response to treatment of patients with lymphoma and myeloma. Although 18F-FDG-PET has been extensively studied in the management of lymphoma, few studies have examined its value for assessing BMI. 18F-FDG-PET seems to be accurate for this purpose in patients with lymphoma and myeloma. The limitations of MR imaging and 18F-FDG-PET will be detailed. In conclusion, MRI and PET imaging including the functional approach of perfusion by DCE-MR imaging and glucose uptake by 18F-FDG-PET can contribute to the management of patients with lymphoproliferative diseases by its ability to analyse BMI.
publisher	BioMed Central
publishDate	2015
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448641/
_version_	1613229312504233984

MRI and PET of bone marrow in lymphoproliferative diseases

Similar Items